The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

被引:53
作者
Crozier, J. E. M. [1 ]
McKee, R. F. [1 ]
McArdle, C. S. [1 ]
Angerson, W. J. [1 ]
Anderson, J. H. [1 ]
Horgan, P. G. [1 ]
McMillan, D. C. [1 ]
机构
[1] Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
关键词
C-reactive protein; albumin; Dukes stage; 5-FU adjuvant chemotherapy; survival; colorectal cancer;
D O I
10.1038/sj.bjc.6603185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (P < 0.001), Dukes stage (P < 0.05) and an elevated C-reactive protein (P < 0.01) were significantly associated with survival. In those patients who did receive adjuvant chemotherapy, an elevated C-reactive protein concentration (P < 0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
引用
收藏
页码:1833 / 1836
页数:4
相关论文
共 27 条
[1]   Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? [J].
Andreyev, HJN ;
Norman, AR ;
Oates, J ;
Cunningham, D .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) :503-509
[2]   Factors affecting cytochrome P-450 3A activity in cancer patients [J].
Baker, SD ;
van Schaik, RHN ;
Rivory, LP ;
ten Tije, AJ ;
Dinh, K ;
Graveland, WJ ;
Schenk, PW ;
Charles, KA ;
Clarke, SJ ;
Carducci, MA ;
McGuire, WP ;
Dawkins, F ;
Gelderblom, H ;
Verweij, J ;
Sparreboom, A .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8341-8350
[3]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[4]   The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer [J].
Bromwich, E ;
McMillan, DC ;
Lamb, GWA ;
Vasey, PA ;
Aitchison, M .
BRITISH JOURNAL OF CANCER, 2004, 91 (07) :1236-1238
[5]   The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer [J].
Canna, K ;
McArdle, PA ;
McMillan, DC ;
McNicol, AM ;
Smith, GW ;
McKee, RF ;
McArdle, CS .
BRITISH JOURNAL OF CANCER, 2005, 92 (04) :651-654
[6]   Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors [J].
Cascinu, S ;
Georgoulias, V ;
Kerr, D ;
Maughna, T ;
Labianca, R ;
Ychou, M .
ANNALS OF ONCOLOGY, 2003, 14 :25-29
[7]   Acute phase response during radiotherapy [J].
Cengiz, M ;
Akbulut, S ;
Atahan, IL ;
Grigsby, PW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (04) :1093-1096
[8]   THE SPREAD OF RECTAL CANCER AND ITS EFFECT ON PROGNOSIS [J].
DUKES, CE ;
BUSSEY, HJR .
BRITISH JOURNAL OF CANCER, 1958, 12 (03) :309-&
[9]   Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer [J].
Forrest, LM ;
McMillan, DC ;
McArdle, CS ;
Angerson, WJ ;
Dunlop, DJ .
BRITISH JOURNAL OF CANCER, 2004, 90 (09) :1704-1706
[10]  
JASS JR, 1987, LANCET, V1, P1303